Biogen Options Trading: A Deep Dive into Market Sentiment
Feb 21, 2025
Biogen Equities
Royal Bank of Canada Lowers Biogen Price Target to $225.00
Feb 14, 2025
Biogen Exceeds Estimates with Cost Reductions and New Therapies, Yet Profit Outlook Falls Short
Feb 12, 2025
What To Expect From Biogen's Q4 Earnings Report
Feb 11, 2025
Analyzing Recent Options Activity for Biogen (NASDAQ: BIIB)
Jan 21, 2025
Biogen (BIIB) Faces Downtrend, But a Turnaround May Be Imminent
Nov 5, 2024
Biogen Reports Positive Outcomes from Higher-Dose Nusinersen Trial in SMA Treatment
Sep 5, 2024
Biogen Announces European Approval for Tocilizumab Biosimilar, TOFIDENCE™
Jun 25, 2024
FDA Approves Eisai's LEQEMBI® Maintenance Dosing Application for Early Alzheimer's Treatment
Jun 10, 2024
European Commission Revokes Marketing Authorizations for Generic TECFIDERA® Variants; Biogen Affected
Dec 20, 2023